Brian R. Tiffany

Brian R. Tiffany

Auto-generated profile, based on publicly available information

Brian R. Tiffany

Department of Emergency Medicine, Chandler Regional Medical Center, Chandler, AZ

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SBSandhya Bansal
Sandhya Bansal
SPSudhir Perincheri
Sudhir Perincheri
TFTimothy Fleming
Timothy Fleming
CPChristin Poulson
Christin Poulson
BTBrian Tiffany
Brian Tiffany
TMThalachallour Mohanakumar
Thalachallour Mohanakumar
Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causes severe acute respiratory syndrome. mRNA vaccines directed at the SARS-CoV-2 spike protein resulted in development of Abs and protective immunity. To determine the mechanism, we analyzed the kinetics of induction of circulating exosomes with SARS-CoV-2 spike protein and Ab following vaccination of healthy individuals. Results demonstrated induction of circulating exosomes expressing spike protein on day 14 after vaccination followed by Abs 14 d after the second dose. Exosomes with spike protein, Abs to SARS-CoV-2 spike, and T cells secreting IFN-γ and TNF-α increased following the booster dose. Transmission electron microscopy of exosomes also demonstrated spike protein Ags on their surface. Exosomes with spike protein and Abs decreased in parallel after four months. These results demonstrate an important role of circulating exosomes with spike protein for effective immunization following mRNA-based vaccination. This is further documented by induction of humoral and cellular immune responses in mice immunized with exosomes carrying spike protein.

6 September 2024 in Clinical and Experimental Emergency Medicine
Verified
Journal Article
Open access
PDF file
WPWilliam Peacock
William Peacock
KSKarina Melissa Soto-Ruiz
Karina Melissa Soto-Ruiz
AJAllan Jaffe
Allan Jaffe
BTBrian R. Tiffany
Brian R. Tiffany
SMSimon A. Mahler
Simon A. Mahler
RCRobert H. Christenson
Robert H. Christenson
Objective: Chest pain, a common emergency department presentation, requires rapid evaluation. The current gold standard of care is serial troponin measurements from blood draws along with an electrocardiogram and clinical presentation. However, an optical technology-based noninvasive wearable device, the Infrasensor, which can rapidly and transcutaneously assesses cardiac troponin I (cTnI), was recently developed. We aimed to perform a pilot study to evaluate the performance of the Infrasensor in cTnI defined cohorts.Methods: This was a 10-hospital prospective observational study in healthy US subjects with a normal cTnI level and in patients with an elevated local cTnI level. Healthy subjects as determined by a negative questionnaire and bloodwork underwent 3-minute Infrasensor measurement and levels of high-sensitivity cTnI (hs-cTnI), n-terminal pro-B-type natriuretic peptide (NTproBNP), creatinine, and glycosylated hemoglobin (HbA1c) were evaluated from blood. Patients with elevated cTnI had the same Infrasensor and blood sample measurements. Using a fivefold cross-validation technique, cTnI-based binary classification models that did and did not include age were trained on 80% and validated on 20% of the dataset (n=168; elevated hs-cTnI equally partitioned into five nearly equally-sized subsets ). Results: Of 840 patients, 727 (87.5%) had normal (nonelevated) cTnI levels while the remaining 113 had elevated cTnI. Median age was 61 years (interquartile range, 52–71 years) for the elevated cohort and 48 years (interquartile range, 32–57 years) for the nonelevated. Overall, 416 (50.5%) were female, with 33 of 113 (29.2%) in the elevated cohort and 383 of 727 (52.7%) in the nonelevated cohort. Overall, the sensitivity, specificity, negative and positive predictive values of the Infrasensor for identifying elevated cTnI were 0.90, 0.70, 0.98 and 0.48, respectively, with a C-statistic of 0.90 (95% confidence interval, 0.89–0.99).Conclusion: The Infrasensor accurately identifies elevated cTnI within 3 minutes of application.